Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2018

01-12-2018 | ASO Author Reflections

ASO Author Reflections: Clinical Value of PET-CT for Gastric Cancer

Authors: Michihiro Kudou, MD, Toshiyuki Kosuga, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2018

Login to get access

Excerpt

Currently, gastric cancer (GC) patients with pathological stage (pStage) II or III are recommended to receive postoperative adjuvant chemotherapy.1 However, survival benefits are still limited and unsatisfactory, particularly in patients with pStage III. Thus, several clinical trials are ongoing to show the superiority of neoadjuvant chemotherapy (NAC) to postoperative chemotherapy for GC patients with clinical stage (cStage) III. The assessment of lymph node metastasis and the stage of GC has generally been performed by computed tomography (CT), and it is very challenging to predict accurately pStage III before surgery because of its low sensitivity and specificity.2 18-fluorodeoxyglucose (FDG) positron emission tomography integrated with CT (PET-CT) has been increasingly used to predict the metastasis of several malignant diseases based on its high specificity. This study focused on the roles of preoperative PET-CT in GC and investigated whether FDG uptake in the primary tumor and/or lymph nodes contributes to the screening of patients with pStage III/IV GC before surgery.3 …
Literature
1.
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRef
2.
Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21(1):68–73.CrossRefPubMed
3.
Kudou M, Kosuga T, Kubota T, et al. Value of preoperative PET-CT in the prediction of pathological stage of gastric cancer. Ann Surg Oncol. 2018;25(6):1633–9.CrossRefPubMed
4.
Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association task force for research promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14(1):13–21.CrossRefPubMed
5.
Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015;2:Cd009944.
Metadata
Title
ASO Author Reflections: Clinical Value of PET-CT for Gastric Cancer
Authors
Michihiro Kudou, MD
Toshiyuki Kosuga, MD
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6845-3

Other articles of this Special Issue 3/2018

Annals of Surgical Oncology 3/2018 Go to the issue

ASO Author Reflections

ASO Author Reflections: Salvage Liver Transplant for Recurrent Hepatocellular Carcinoma After Treatments With Curative Intent

ASO Author Reflections

ASO Author Reflections: Nodal Skip Metastasis in Esophageal Squamous Cell Carcinoma

ASO Author Reflections

ASO Author Reflections: The Role of Tumor Size in the Prognosis of Anal Squamous Cell Carcinoma: A Validation on the New American Joint Committee on Cancer Subclassification of Stage IIA and B

ASO Author Reflections

ASO Author Reflections: Prolonged Immunoparalysis of NK Cells After Surgery

ASO Author Reflections

ASO Author Reflections: Use of Retrospective Administrative Datasets in Rare Cancer Subtypes to Determine the Efficacy of Adjuvant Therapy

ASO Author Reflections

ASO Author Reflections: Reducing Axillary Lymph Node Dissections in Node-Positive Breast Cancer Patients